Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-label Trial to Evaluate Target Occupancy of CVL-354 at Kappa Opioid and Mu Opioid Receptors in Brain Following Single Oral Doses in Healthy Participants Using Positron Emission Tomography

Next Previous
Trial Profile

A Phase 1, Open-label Trial to Evaluate Target Occupancy of CVL-354 at Kappa Opioid and Mu Opioid Receptors in Brain Following Single Oral Doses in Healthy Participants Using Positron Emission Tomography

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carfentanil (Primary) ; Icalcaprant (Primary) ; LY 2795050 (Primary)
  • Indications Opioid-related disorders
  • Focus Pharmacodynamics
  • Sponsors Cerevel Therapeutics

Most Recent Events

  • 26 Aug 2024 Status changed from recruiting to completed.
  • 01 Aug 2024 According to an AbbVie media release, AbbVie has acquired Cerevel Therapeutics.
  • 18 May 2023 Planned End Date changed from 1 Feb 2024 to 1 Jun 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top